Neil Fleshner, MD, MPH, Princess Margaret Cancer Centre, Toronto, Canada, talks on unmet needs in patients with prostate cancer. High-risk patients have an increased risk of developing metastases, an area where PET scans will be of significant value. PET scans can improve the detection of patients with truly metastatic or high-risk/locally advanced disease, thus enabling the selection of the most appropriate treatment regimen. Dr Fleshner explains the ultimate goal being the development of novel therapies to encourage disease-free survival and thereby prevent the need for further treatment. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.